Download PDF
Semin Thromb Hemost
DOI: 10.1055/s-0044-1785485
Review Article

Reviewing the Rich History of Fibrin Clot Research with a Focus on Clinical Relevance

Anetta Undas
1   Department of Thromboembolic Diseases, Institute of Cardiology, Jagiellonian University Medical College, and Center for Research and Medical Technology, John Paul II Hospital, Cracow, Poland
› Author Affiliations Funding This work was supported by the Jagiellonian University Medical College (N/41/DBS/001040 to A.U.).
› Further Information
    Permissions and Reprints

Abstract

Fibrin, described on a single-lens microscopy for the first time by Malpighi in 1666 and named by de Fourcroy, has been extensively studied by biochemists, biophysicists, and more recently by clinicians who recognized that fibrin is the major component of most thrombi. Elucidation of key reactions leading to fibrin clot formation in the 1950s and 1960s grew interest in the clinical relevance of altered fibrin characteristics. Implementation of scanning electron microscopy to image fibrin clots in 1947 and clot permeation studies in the 1970s to evaluate an average pore size enabled plasma clot characterization in cohorts of patients. Unfavorably altered fibrin clot structure was demonstrated by Blombäck's group in coronary artery disease in 1992 and in diabetes in 1996. Fifteen years ago, similar plasma fibrin clot alterations were reported in patients following venous thromboembolism. Multiple myeloma was the first malignant disease to be found to lead to abnormal fibrin clot phenotype in the 1970s. Apart from anticoagulant agents, in 1998, aspirin was first shown to increase fibrin clot permeability in cardiovascular patients. The current review presents key data on the rich history of fibrin research, in particular, those that first documented abnormal fibrin clot properties in a variety of human disease states, as well as factors affecting fibrin phenotype.

Keywords

fibrin clot - disease - medication - risk factors


Publication History

Article published online:
11 April 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Litvinov RI, Weisel JW. What is the biological and clinical relevance of fibrin?. Semin Thromb Hemost 2016; 42 (04) 333-343
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Litvinov RI, Pieters M, de Lange-Loots Z, Weisel JW. Fibrinogen and fibrin. Subcell Biochem 2021; 96: 471-501
    CrossrefPubMedGoogle Scholar
  • 3 Wolberg AS. Fibrinogen and fibrin: synthesis, structure, and function in health and disease. J Thromb Haemost 2023; 21 (11) 3005-3015
    CrossrefPubMedGoogle Scholar
  • 4 Forrester JM. Malpighi's De polypo cordis: an annotated translation. Med Hist 1995; 39 (04) 477-492
    CrossrefPubMedGoogle Scholar
  • 5 Weisel JW, Litvinov RI. Visualizing thrombosis to improve thrombus resolution. Res Pract Thromb Haemost 2021; 5 (01) 38-50
    CrossrefPubMedGoogle Scholar
  • 6 Costa-Filho R, Hochleitner G, Wendt M, Teruya A, Spahn DR. Over 50 years of fibrinogen concentrate. Clin Appl Thromb Hemost 2016; 22 (02) 109-114
    CrossrefPubMedGoogle Scholar
  • 7 Rosenfeld L. The fibrinogen to fibrin transformation. In: Origins of Clinical Chemistry: The Evolution of Protein Analysis. New York, NY:: Academic Press;; 1982: 366
    Google Scholar
  • 8 Owen Jr CA. A History of Blood Coagulation. Mayo Foundation for Medical Education and Research.; 2001
    Google Scholar
  • 9 Mihalyi E. Electrophoretic investigation of fibrin and fibrinogen dissolved in urea solutions. Acta Chem Scand 1950; 4: 351-358
    CrossrefPubMedGoogle Scholar
  • 10 Laki K. The polymerization of proteins; the action of thrombin on fibrinogen. Arch Biochem Biophys 1951; 32 (02) 317-324
    CrossrefPubMedGoogle Scholar
  • 11 Lorand L. A study on the solubility of fibrin clots in urea. Hung Acta Physiol 1948; 1 (06) 192-196
    PubMedGoogle Scholar
  • 12 Bailey K, Bettelheim FR, Lorand L, Middlebrook WR. Action of thrombin in the clotting of fibrinogen. Nature 1951; 167 (4241) 233-234
    CrossrefPubMedGoogle Scholar
  • 13 Lorand L. Fibrino-peptide. Biochem J 1952; 52: 200-203
    CrossrefPubMedGoogle Scholar
  • 14 Ferry JD. The mechanism of polymerization of fibrin. Proc Natl Acad Sci U S A 1952; 38 (07) 566-569
    CrossrefPubMedGoogle Scholar
  • 15 Hermans J, McDonagh J. Fibrin: structure and interactions. Semin Thromb Hemost 1982; 8 (01) 11-24
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Doolittle RF. Fibrinogen and fibrin. Annu Rev Biochem 1984; 53: 195-229
    CrossrefPubMedGoogle Scholar
  • 17 Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 1992; 29 (03) 177-188
    PubMedGoogle Scholar
  • 18 Hall CE. Electron microscopy of fibrinogen and fibrin. J Biol Chem 1949; 179 (02) 857-864
    CrossrefPubMedGoogle Scholar
  • 19 Hantgan RR, Hermans J. Assembly of fibrin. A light scattering study. J Biol Chem 1979; 254 (22) 11272-11281
    CrossrefPubMedGoogle Scholar
  • 20 Weisel JW, Nagaswami C, Makowski L. Twisting of fibrin fibers limits their radial growth. Proc Natl Acad Sci U S A 1987; 84 (24) 8991-8995
    CrossrefPubMedGoogle Scholar
  • 21 Drake B, Prater CB, Weisenhorn AL. et al. Imaging crystals, polymers, and processes in water with the atomic force microscope. Science 1989; 243 (4898) 1586-1589
    CrossrefPubMedGoogle Scholar
  • 22 Roberts WW, Lorand L, Mockros LF. Viscoelastic properties of fibrin clots. Biorheology 1973; 10 (01) 29-42
    CrossrefPubMedGoogle Scholar
  • 23 Gerth C, Roberts WW, Ferry JD. Rheology of fibrin clots. II. Linear viscoelastic behavior in shear creep. Biophys Chem 1974; 2 (03) 208-217
    CrossrefPubMedGoogle Scholar
  • 24 Guthold M, Liu W, Stephens B. et al. Visualization and mechanical manipulations of individual fibrin fibers suggest that fiber cross section has fractal dimension 1.3. Biophys J 2004; 87 (06) 4226-4236
    CrossrefPubMedGoogle Scholar
  • 25 Liu W, Jawerth LM, Sparks EA. et al. Fibrin fibers have extraordinary extensibility and elasticity. Science 2006; 313 (5787) 634
    CrossrefPubMedGoogle Scholar
  • 26 Brown AEX, Litvinov RI, Discher DE, Purohit PK, Weisel JW. Multiscale mechanics of fibrin polymer: gel stretching with protein unfolding and loss of water. Science 2009; 325 (5941) 741-744
    CrossrefPubMedGoogle Scholar
  • 27 Chernysh IN, Weisel JW. Dynamic imaging of fibrin network formation correlated with other measures of polymerization. Blood 2008; 111 (10) 4854-4861
    CrossrefPubMedGoogle Scholar
  • 28 He S, Wallén H, Thålin C, Svensson J, Blombäck M. Fibrin network porosity and endo-/exogenous thrombin cross-talk. Semin Thromb Hemost 2021; 47 (07) 775-786
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Van Zandt Hawn C, Porter KR. The fine structure of clots formed from purified bovine fibrinogen and thrombin: a study with the electron microscope. J Exp Med 1947; 86 (04) 285-292
    CrossrefPubMedGoogle Scholar
  • 30 Ferry JD, Morrison PR. Preparation and properties of serum and plasma proteins; the conversion of human fibrinogen to fibrin under various conditions. J Am Chem Soc 1947; 69 (02) 388-400
    CrossrefPubMedGoogle Scholar
  • 31 Ferry JD. Protein gels. Adv Protein Chem 1948; 4: 1-78
    CrossrefPubMedGoogle Scholar
  • 32 Signer R, Egli H. Sedimentation von Makromolekülen und Durchströmung von Gelen. Rec Trav Chim 1950; 69: 45-58
    CrossrefPubMedGoogle Scholar
  • 33 Carr Jr ME, Shen LL, Hermans J. Mass-length ratio of fibrin fibers from gel permeation and light scattering. Biopolymers 1977; 16 (01) 1-15
    CrossrefPubMedGoogle Scholar
  • 34 Blombäck B, Okada M. Fibrin gel structure and clotting time. Thromb Res 1982; 25 (1-2): 51-70
    CrossrefPubMedGoogle Scholar
  • 35 Okada M, Blombäck B. Factors influencing fibrin gel structure studied by flow measurement. Ann N Y Acad Sci 1983; 408: 233-253
    CrossrefPubMedGoogle Scholar
  • 36 Carr ME. Fibrin formed in plasma is composed of fibers more massive than those formed from purified fibrinogen. Thromb Haemost 1988; 59 (03) 535-539
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Galanakis DK, Lane BP, Simon SR. Albumin modulates lateral assembly of fibrin polymers: evidence of enhanced fine fibril formation and of unique synergism with fibrinogen. Biochemistry 1987; 26 (08) 2389-2400
    CrossrefPubMedGoogle Scholar
  • 38 Gabriel DA, Smith LA, Folds JD, Davis L, Cancelosi SE. The influence of immunoglobulin (IgG) on the assembly of fibrin gels. J Lab Clin Med 1983; 101 (04) 545-552
    PubMedGoogle Scholar
  • 39 Carr ME, White II GC, Gabriel DA. Platelet factor 4 enhances fibrin fiber polymerization. Thromb Res 1987; 45 (05) 539-543
    CrossrefPubMedGoogle Scholar
  • 40 Bale MD, Westrick LG, Mosher DF. Incorporation of thrombospondin into fibrin clots. J Biol Chem 1985; 260 (12) 7502-7508
    CrossrefPubMedGoogle Scholar
  • 41 Blombäck B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75 (05) 521-538
    CrossrefPubMedGoogle Scholar
  • 42 Wolberg AS, Monroe DM, Roberts HR, Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood 2003; 101 (08) 3008-3013
    CrossrefPubMedGoogle Scholar
  • 43 Pieters M, Undas A, Marchi R, De Maat MP, Weisel J, Ariëns RA. Factor XIII And Fibrinogen Subcommittee Of The Scientific Standardisation Committee Of The International Society For Thrombosis And Haemostasis. An international study on the standardization of fibrin clot permeability measurement: methodological considerations and implications for healthy control values. J Thromb Haemost 2012; 10 (10) 2179-2181
    CrossrefPubMedGoogle Scholar
  • 44 Wolberg AS, Sang Y. Fibrinogen and factor XIII in venous thrombosis and thrombus stability. Arterioscler Thromb Vasc Biol 2022; 42 (08) 931-941
    CrossrefPubMedGoogle Scholar
  • 45 Mills JD, Ariëns RAS, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106 (15) 1938-1942
    CrossrefPubMedGoogle Scholar
  • 46 Undas A, Zawilska K, Ciesla-Dul M. et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114 (19) 4272-4278
    CrossrefPubMedGoogle Scholar
  • 47 Dunn EJ, Ariëns RA, de Lange M. et al. Genetics of fibrin clot structure: a twin study. Blood 2004; 103 (05) 1735-1740
    CrossrefPubMedGoogle Scholar
  • 48 Williams FM, Carter AM, Kato B. et al; EuroCLOT Investigators. Identification of quantitative trait loci for fibrin clot phenotypes: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2009; 29 (04) 600-605
    CrossrefPubMedGoogle Scholar
  • 49 Standeven KF, Uitte de Willige S, Carter AM, Grant PJ. Heritability of clot formation. Semin Thromb Hemost 2009; 35 (05) 458-467
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Casini A, Duval C, Pan X, Tintillier V, Biron-Andreani C, Ariëns RAS. Fibrin clot structure in patients with congenital dysfibrinogenaemia. Thromb Res 2016; 137: 189-195
    CrossrefPubMedGoogle Scholar
  • 51 Mammen EF, Prasad AS, Barnhart MI, Au CC. Congenital dysfibrinogenemia: fibrinogen Detroit. J Clin Invest 1969; 48 (02) 235-249
    CrossrefPubMedGoogle Scholar
  • 52 Casini A, Moerloose P, Neerman-Arbez M. One hundred years of congenital fibrinogen disorders. Semin Thromb Hemost 2022; 48 (08) 880-888
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Collet JP, Soria J, Mirshahi M. et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood 1993; 82 (08) 2462-2469
    CrossrefPubMedGoogle Scholar
  • 54 Duckert F, Jung E, Shmerling DH. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh 1960; 5: 179-186
    PubMedGoogle Scholar
  • 55 Kurniawan NA, Grimbergen J, Koopman J, Koenderink GH. Factor XIII stiffens fibrin clots by causing fiber compaction. J Thromb Haemost 2014; 12 (10) 1687-1696
    CrossrefPubMedGoogle Scholar
  • 56 Carlisle CR, Sparks EA, Der Loughian C, Guthold M. Strength and failure of fibrin fiber branchpoints. J Thromb Haemost 2010; 8 (05) 1135-1138
    CrossrefPubMedGoogle Scholar
  • 57 Ariëns RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96 (03) 988-995
    CrossrefPubMedGoogle Scholar
  • 58 Ajjan R, Lim BC, Standeven KF. et al. Common variation in the C-terminal region of the fibrinogen β-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood 2008; 111 (02) 643-650
    CrossrefPubMedGoogle Scholar
  • 59 Lim BC, Ariëns RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361 (9367) 1424-1431
    CrossrefPubMedGoogle Scholar
  • 60 Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariëns RA. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003; 107 (18) 2326-2330
    CrossrefPubMedGoogle Scholar
  • 61 Cooper AV, Standeven KF, Ariëns RA. Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure. Blood 2003; 102 (02) 535-540
    CrossrefPubMedGoogle Scholar
  • 62 Fatah K, Hamsten A, Blombäck B, Blombäck M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68 (02) 130-135
    Article in Thieme ConnectPubMedGoogle Scholar
  • 63 Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Aslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997 (1-2): 96-110
    CrossrefPubMedGoogle Scholar
  • 64 Bini A, Fenoglio Jr JJ, Mesa-Tejada R, Kudryk B, Kaplan KL. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies. Arteriosclerosis 1989; 9 (01) 109-121
    CrossrefPubMedGoogle Scholar
  • 65 Chernysh IN, Nagaswami C, Kosolapova S. et al. The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli. Sci Rep 2020; 10 (01) 5112
    CrossrefPubMedGoogle Scholar
  • 66 Silvain J, Collet J-P, Nagaswami C. et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol 2011; 57 (12) 1359-1367
    CrossrefPubMedGoogle Scholar
  • 67 Williams S, Fatah K, Hjemdahl P, Blombäck M. Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid. Eur Heart J 1998; 19 (11) 1666-1672
    CrossrefPubMedGoogle Scholar
  • 68 Kwaan HC, Lindholm PF. Fibrin and fibrinolysis in cancer. Semin Thromb Hemost 2019; 45 (04) 413-422
    Article in Thieme ConnectPubMedGoogle Scholar
  • 69 Litvinov RI, Nabiullina RM, Zubairova LD, Shakurova MA, Andrianova IA, Weisel JW. Lytic susceptibility, structure, and mechanical properties of fibrin in systemic lupus erythematosus. Front Immunol 2019; 10: 1626
    CrossrefPubMedGoogle Scholar
  • 70 Wygrecka M, Birnhuber A, Seeliger B. et al. Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19. Blood Adv 2022; 6 (03) 1074-1087
    CrossrefPubMedGoogle Scholar
  • 71 Undas A, Szułdrzynski K, Stepien E. et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2008; 196 (02) 551-557
    CrossrefPubMedGoogle Scholar
  • 72 Undas A, Slowik A, Wolkow P, Szczudlik A, Tracz W. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. Thromb Res 2010; 125 (04) 357-361
    CrossrefPubMedGoogle Scholar
  • 73 Undas A, Podolec P, Zawilska K. et al. Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke. Stroke 2009; 40 (04) 1499-1501
    CrossrefPubMedGoogle Scholar
  • 74 Martinez MR, Cuker A, Mills AM. et al. Enhanced lysis and accelerated establishment of viscoelastic properties of fibrin clots are associated with pulmonary embolism. Am J Physiol Lung Cell Mol Physiol 2014; 306 (05) L397-L404
    CrossrefPubMedGoogle Scholar
  • 75 Jörneskog G, Egberg N, Fagrell B. et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 1996; 39 (12) 1519-1523
    CrossrefPubMedGoogle Scholar
  • 76 Colle JP, Mishal Z, Lesty C. et al. Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications: a possible mechanism for the high thrombotic tendency?. Thromb Haemost 1999; 82 (05) 1482-1489
    PubMedGoogle Scholar
  • 77 Lackner H, Hunt V, Zucker MB, Pearson J. Abnormal fibrin ultrastructure, polymerization, and clot retraction in multiple myeloma. Br J Haematol 1970; 18 (06) 625-636
    CrossrefPubMedGoogle Scholar
  • 78 Sjøland JA, Sidelmann JJ, Brabrand M. et al. Fibrin clot structure in patients with end-stage renal disease. Thromb Haemost 2007; 98 (02) 339-345
    PubMedGoogle Scholar
  • 79 Undas A, Topór-Madry R, Tracz W, Pasowicz M. Effect of cigarette smoking on plasma fibrin clot permeability and susceptibility to lysis. Thromb Haemost 2009; 102 (06) 1289-1291
    PubMedGoogle Scholar
  • 80 Rajzer M, Wojciechowska W, Kawecka-Jaszcz K, Undas A. Plasma fibrin clot properties in arterial hypertension and their modification by antihypertensive medication. Thromb Res 2012; 130 (01) 99-103
    CrossrefPubMedGoogle Scholar
  • 81 Fatah K, Silveira A, Tornvall P, Karpe F, Blombäck M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76 (04) 535-540
    Article in Thieme ConnectPubMedGoogle Scholar
  • 82 Undas A, Stepien E, Tracz W, Szczeklik A. Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J Thromb Haemost 2006; 4 (05) 973-975
    CrossrefPubMedGoogle Scholar
  • 83 Standeven KF, Ariëns RAS, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 2002; 51 (01) 189-197
    CrossrefPubMedGoogle Scholar
  • 84 Undas A, Celinska-Löwenhoff M, Löwenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 4 (05) 1029-1036
    CrossrefPubMedGoogle Scholar
  • 85 Jörneskog G, Hansson L-O, Wallen NH, Yngen M, Blombäck M. Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion. J Thromb Haemost 2003; 1 (06) 1195-1201
    CrossrefPubMedGoogle Scholar
  • 86 Gajos G, Zalewski J, Rostoff P, Nessler J, Piwowarska W, Undas A. Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). Arterioscler Thromb Vasc Biol 2011; 31 (07) 1696-1702
    CrossrefPubMedGoogle Scholar
  • 87 Ząbczyk M, Majewski J, Karkowski G, Malinowski KP, Undas A. Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3days of treatment: Relation to coagulation factors and thrombin generation. Thromb Res 2015; 136 (04) 832-838
    CrossrefPubMedGoogle Scholar
  • 88 He S, Blombäck M, Bark N, Johnsson H, Wallén NH. The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis. Thromb Haemost 2010; 103 (05) 1076-1084
    Article in Thieme ConnectPubMedGoogle Scholar